Sergio Barberan-Soler's Biography

Sergio Barberan-Soler, CEO, RealSeq Biosciences

Sergio Barberan-Soler is the CEO at RealSeq Biosciences, Inc. He oversees technology development and innovative products to facilitate non-coding small RNA analysis by Next Generation Sequencing. Dr. Barberan-Soler is involved in numerous product development efforts to allow for more accurate quantification of RNA from diverse samples types. Prior to joining RealSeq Biosciences, Dr. Barberan-Soler was the Director of Sequencing Technologies at Somagenics Inc, before that he was a postdoctoral fellow at the CRG in Barcelona and previously received his PhD in Molecular, Cell and Developmental Biology from the University of California, Santa Cruz.

Highly Sensitive Direct Quantification of cf-microRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)

Tuesday, 18 February 2020 at 09:30

Add to Calendar ▼2020-02-18 09:30:002020-02-18 10:30:00Europe/LondonHighly Sensitive Direct Quantification of cf-microRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)Circulating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Cell-free circulating microRNAs (cf-miRNAs) are promising diagnostic and prognostic biomarkers for cancer and other diseases. cf-miRNAs are highly stable in biofluids and are therefore attractive as potential biomarkers via NGS-based detection compared to circulating DNA and protein markers. However, NGS detection of cf-miRNAs suffers from a high level of incorporation bias when sequencing libraries are prepared using the most widely used commercial kits. SomaGenics RealSeq library prep platform addresses this issue, with proven best-in-class accuracy of detection. The RealSeq platform includes a kit designed to profile miRNAs from biofluids (RealSeq-Biofluids) that typically detects four times as many cf-miRNAs as commercially available technologies. The latest kit in the RealSeq platform is RealSeq-T, the first targeted sequencing approach to detect panels of cf-miRNAs (up to 1,200) directly from plasma, with no organic extraction needed. Nearly 95% of sequenced reads from RealSeq-T libraries mapped to the miRNA panel. With these new capabilities, the RealSeq platform should advance the prospects of cf-miRNAs as clinical biomarkers.

Add to Calendar ▼2020-02-17 00:00:002020-02-18 00:00:00Europe/LondonCirculating Biomarkers World Congress 2020Circulating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors